George Rehm

Sensovation AG manufactures and supplies scientific imaging instrumentation products. The firm specializes in the development and production of scientific imaging and low light detection solutions, based on charge coupled device and complementary metal oxide semiconductor technologies. It offers automated digital microscopes, microarray analyzers, and scientific cameras for bioimaging, diagnostics, and quality control in clean technology applications. It also engages in partnerships focused on building and supplying commercial production systems and platforms. The company was founded by Stefan Bickert and Paul Hing in 2000 and is headquartered in Radolfzell, Germany.

Barnev, Inc. is a healthcare information technology company specializing in the development, manufacturing, and marketing of comprehensive monitoring and information solutions to clinicians and hospitals for labor and delivery. The firm is the first to market with delivery suite/product solutions that improve the clinical management of patients, and improve economic efficiency for its customers. Its first product, the BirthTrack™ Continuous Labor Monitoring System, is the most exciting innovation in labor progression monitoring since the Friedman Labor Curve was introduced over 50 years ago. The BirthTrack System is a revolutionary continuous labor monitoring technology that provides obstetric caregivers invaluable, precise, objective, real-time information about the physical progress of labor.

Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Calibrium Private Investments GmbH (formerly Aeris Capital AG) is a venture capital firm with headquarters in Zurich, Switzerland. The firm was founded in 2006.

ViaLogy LLC develops technology to improve signal detection against electronic background noise. Its products include SPM, MicroSPM, MPEX Electronic Eye, REPAS, and QRI. The company was founded in 1999 by Sandeep Gulati and is headquartered in Altadena, CA.

Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients.

ViaLogy Plc provides reservoir characterization, geophysical imaging and hydrocarbon sizing services to global oil and gas customers based on proprietary, patented active signal processing technology. Its product, QuantumRD, is a new technology for the discovery, validation, and recovery of oil and gas reservoirs. The company was founded in 1999 and is headquartered in Gifford, the United Kingdom.

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.